Global research trends and hotspots in metabolomics of osteosarcoma: a decade-spanning bibliometric and visualized analysis DOI Creative Commons
Junbo Tu, Tao Liu, Junfeng Li

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Oct. 9, 2024

Object Osteosarcoma is a malignant tumor originating from the bones, commonly found in children and adolescents, especially rapidly growing bone areas such as knees upper arms. In this study, we aim to delineate evolution convergence of research themes osteosarcoma metabolomics over past decade, identify major contributors, forecast emerging trends that could direct future efforts. Method The bibliometric method has been applied systematically analyze literature field metabolomics. relevant literatures were collected Web Science Core Collection, spanning January 1, 2014, December 31, 2023. Tools CiteSpace, Bibliometrix, VOSviewer used for visual analysis literatures. focused information includes institutions, journals, countries, authors, keywords, citations. Result Various aspects metabolism analyzed. Shanghai Jiao Tong University published most papers ten years, followed by Central South Zhejiang University. Among sources, international journal molecular sciences publishes articles, oncotarget with highest H index. According Bradford’s law, there are 34 core journals identified. A total 5501 authors participated creation field. distribution follows Lotka`s Law, 85.3% have only one article. 46% corresponding China, but these not good at cooperation. China also largest number publications, United States. It can be confirmed dominates “expression” keyword received attention years. All keywords divided into 9 clusters. Based on explosive words hot topics each year, speculate will focus microenvironment, mechanisms autophagy, targeted therapies inhibitors. Conclusion summary, study comprehensively analyzed current state through methods. findings revealed development hotspots field, which may provide valuable references directions.

Language: Английский

Progress in immune microenvironment, immunotherapy and prognostic biomarkers in pediatric osteosarcoma DOI Creative Commons
Lin Zhang,

Haoming Jiang,

Hongzhi Ma

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: Jan. 22, 2025

Pediatric osteosarcoma, the most prevalent primary malignant bone tumor in children, is marked by aggressive progression and a generally poor prognosis. Despite advances treatment, including multi-agent chemotherapy, survival rates remain suboptimal, with metastasis, particularly to lungs, contributing significantly mortality. The microenvironment plays crucial role osteosarcoma progression, immune cells such as tumor-associated macrophages T lymphocytes influencing behavior. immunosuppressive environment, dominated M2 macrophages, contributes evasion therapeutic outcomes, though recent findings suggest potential for reprogramming these enhance responses. This review provides comprehensive overview of landscape pediatric focus on their interactions within (TME). It examines impact checkpoints, genetic mutations, inflammatory pathways highlighting contribution disease advancement. Additionally, emerging immunotherapeutic strategies, checkpoint inhibitors, macrophage reprogramming, antibody-based therapies, are summarized detail, showcasing improve outcomes.

Language: Английский

Citations

1
Targeted anti-angiogenesis therapy for advanced osteosarcoma DOI Creative Commons

Qiao Zhang,

Yuxuan Xia,

Liyuan Wang

et al.

Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14

Published: Aug. 26, 2024

To date, despite extensive research, the prognosis of advanced osteosarcoma has not improved significantly. Thus, patients experience a reduced survival rate, suggesting that reevaluation current treatment strategies is required. Recently, in addition to routine surgery, chemotherapy and radiotherapy, researchers have explored more effective safer treatments, including targeted therapy, immunotherapy, anti-angiogenesis metabolic targets nanomedicine therapy. The tumorigenesis development closely related angiogenesis. therapy crucial treat osteosarcoma; however, recent clinical trials found it insufficient efficacy. solve this problem, causes failure improve should be investigated. This review focuses on summarizing pathophysiological mechanisms angiogenesis advances osteosarcoma. We also discuss some studies, with aim providing new ideas for patients.

Language: Английский

Citations

4
Digging Through the Complexities of Immunological Approaches in Emerging Osteosarcoma Therapeutics: A Comprehensive Narrative Review with Updated Clinical Trials DOI Creative Commons
Consolato Sergi,

Mervin Burnett,

Eugeniu Jantuan

et al.

Biomedicines, Journal Year: 2025, Volume and Issue: 13(3), P. 664 - 664

Published: March 8, 2025

Osteosarcoma (OS) is the predominant mesenchymal primary malignant bone tumor in oncology and pathology, impacting a wide age range from adolescents to older adults. It frequently advances lung metastasis, ultimately resulting mortality of OS patients. The precise pathological pathways responsible for progression dissemination are not fully understood due its heterogeneity. integration surgery with neoadjuvant postoperative chemotherapy has significantly increased 5-year survival rate more than 70% patients localized tumors. However, about 30% experience local recurrence and/or metastasis. Hence, there requirement innovative therapeutic approaches address limitations traditional treatments. Immunotherapy garnered increasing attention as promising avenue tumors resistant standard therapies, including OS, despite underlying mechanisms disease remaining well elucidated. may have been suitable use because tumor’s immunosuppressive microenvironment limited immunogenicity. Nevertheless, immune-based treatments now being developed clinical use, such bispecific antibodies, chimeric antigen receptor T cells, immune checkpoint inhibitors. Also, additional immunotherapy techniques cytokines, vaccines, modified-Natural Killer (NK) cells/macrophages early phases research but will certainly be popular subjects nearest future. Our goal writing this review was spark new lines inquiry into by summarizing findings both preclinical current studies examining different approaches.

Language: Английский

Citations

0
Integrative single-cell and bulk RNA-seq analysis identifies lactylation-related signature in osteosarcoma DOI

Xie Zhou,

Xiao Qu, Jun Zhang

et al.

Functional & Integrative Genomics, Journal Year: 2025, Volume and Issue: 25(1)

Published: March 12, 2025

Language: Английский

Citations

0
Principles of Immunotherapy and Novel Immunotherapeutic Agents for Pediatric Cancer Management DOI
Zachary Morrison, Ali Suliman

Published: Jan. 1, 2025

Language: Английский

Citations

0
Advancements in Osteosarcoma Therapy: Overcoming Chemotherapy Resistance and Exploring Novel Pharmacological Strategies DOI Creative Commons
Mahmoud Zhra, Shahid Akhtar Akhund,

Khalid S. Mohammad

et al.

Pharmaceuticals, Journal Year: 2025, Volume and Issue: 18(4), P. 520 - 520

Published: April 3, 2025

Osteosarcoma is recognized as the most prevalent primary bone malignancy, primarily affecting children and adolescents. It characterized by its aggressive behavior high metastatic potential, which often leads to poor patient outcomes. Despite advancements in surgical techniques chemotherapy regimens, prognosis for patients with osteosarcoma remains unsatisfactory, survival rates plateauing over past few decades. A significant barrier effective treatment development of resistance, complicates management disease contributes recurrence. This review article aims provide a comprehensive overview recent therapy, particularly overcoming resistance. We begin discussing current standard modalities, including resection conventional agents such methotrexate, doxorubicin, cisplatin. While these approaches have been foundational managing osteosarcoma, they are limited adverse effects variability efficacy among patients. To address challenges, we explore novel pharmacological strategies that aim enhance includes targeted therapies focusing on specific molecular alterations cells immunotherapeutic designed harness body’s immune system against tumors. Additionally, innovative drug delivery systems improve bioavailability existing treatments while minimizing toxicity. The also assesses mechanisms underlying efflux mechanisms, altered metabolism, enhanced DNA repair pathways. By synthesizing research findings, highlight potential new therapeutic resistance mechanisms. Ultimately, this seeks inform future directions clinical practices, underscoring need continued innovation treating outcomes rates.

Language: Английский

Citations

0
Advances in cell therapy for orthopedic diseases: bridging immune modulation and regeneration DOI Creative Commons
Jing Wang,

Shenghao Xu,

Bo Chen

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: April 10, 2025

Orthopedic diseases pose significant challenges to public health due their high prevalence, debilitating effects, and limited treatment options. Additionally, orthopedic tumors, such as osteosarcoma, chondrosarcoma, Ewing sarcoma, further complicate the landscape. Current therapies, including pharmacological treatments joint replacement, address symptoms but fail promote true tissue regeneration. Cell-based which have shown successful clinical results in cancers other diseases, emerged a promising solution repair damaged tissues restore function tumors. This review discusses advances potential application of cell therapy for with particular focus on osteoarthritis, bone fractures, cartilage degeneration, We explore mesenchymal stromal cells (MSCs), chondrocyte transplantation, engineered immune induced pluripotent stem enhance regeneration by modulating response addressing inflammation. Ultimately, integration cutting-edge therapy, modulation, molecular targeting strategies could revolutionize providing hope patients seeking long-term solutions conditions.

Language: Английский

Citations

0
Advanced-Therapy Medicinal Products: Challenges for Implementation in Pediatric Clinical Practice DOI Creative Commons
Yu. М. Gomon, А. С. Колбин

Вопросы современной педиатрии, Journal Year: 2024, Volume and Issue: 23(1), P. 34 - 47

Published: Feb. 25, 2024

The article discusses classifications of medicines for gene and cell therapy. Data on medicinal products registered in Russia, as well the European Union countries, Great Britain, USA, Japan is presented. limitations using such were considered, including their high utilitarian cost risk adverse events. potential increasing clinical efficacy economic feasibility advanced therapies (pediatrics included) has been analyzed.

Language: Английский

Citations

1
RNA modification‐related EIF4G2 is an immunotherapy determinant in osteosarcoma: A single‐cell sequencing analysis DOI
Haocheng Qin,

Shu Yang,

Zhennan Feng

et al.

Environmental Toxicology, Journal Year: 2024, Volume and Issue: 39(10), P. 4547 - 4561

Published: April 5, 2024

Abstract The clinical outcomes of osteosarcoma are relatively dismal. As immunotherapy has revolutionized treatment for solid tumors, exploring novel immunotherapy‐related therapeutic targets is important. In this study, we aimed to establish the connection between RNA modification and in identify targets. An modification‐related signature was first developed using weight gene correlation network analysis a machine‐learning algorithm, random forest. signature's prognostic value, drug prediction, immune characteristics were analyzed. EIF4G2 from next identified as critical determinant. could also promote tumor proliferation, migration, M2 macrophage migration by single‐cell sequencing vitro validation. Our expected provide valuable insights into management osteosarcoma.

Language: Английский

Citations

0
Downregulation of PRKCI inhibits osteosarcoma cell growth by inactivating the Akt/mTOR signaling pathway DOI Creative Commons
Liujing Qu, Xin Yu,

Jieni Feng

et al.

Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14

Published: July 2, 2024

PRKCI is abnormally expressed in various cancers, but its role osteosarcoma unknown. This study aimed to explore the biological function of and potential molecular mechanism. expression was evaluated cell lines using Western blot analysis reverse transcription PCR. The CCK-8 assay, colony formation flow cytometry, Transwell wound-healing assay were used detect proliferation, colony-forming capacity, cycle, migration, invasion cells when overexpressed or knocked down. interaction between SQSTM1 explored immunoprecipitation. Finally, protein molecule Akt/mTOR signaling pathway detected Our found that lines. overexpression promoted proliferation capacity cells, while silencing inhibited arrested cycle at G2/M phase. Both osteosarcoma. only related histological type, not clinical characteristics. higher than chondrosarcoma. Knockdown by inactivating pathway, suggesting a target for therapy.

Language: Английский

Citations

0